Tuberculosis in Europe & Central Asia
Country-level tuberculosis mortality data for Europe & Central Asia. Age-standardized death rates per 100,000 population from the IHME Global Burden of Disease Study.
| # | Country | Rate |
|---|
This page presents tuberculosis mortality data for countries in Europe & Central Asia, using age-standardized death rates per 100,000 population from the Institute for Health Metrics and Evaluation (IHME). Regional analysis reveals significant variation in disease burden between countries, reflecting differences in healthcare infrastructure, socioeconomic conditions, environmental risk factors, and public health policy implementation across Europe & Central Asia.
Tuberculosis (TB) is caused by Mycobacterium tuberculosis, an airborne bacterium that primarily infects the lungs but can disseminate to virtually any organ. Roughly one-quarter of the global population carries latent TB infection, of whom 5-10% will develop active disease in their lifetime — a risk dramatically amplified by HIV co-infection, diabetes, malnutrition, and immunosuppression. TB kills through progressive cavitary lung destruction, haemoptysis, respiratory failure, and systemic wasting. It remains the leading infectious disease killer worldwide in non-pandemic years, claiming approximately 1.3 million lives annually among HIV-negative individuals and an additional 167,000 among people living with HIV. Eight countries account for two-thirds of the global burden: India, Indonesia, China, the Philippines, Pakistan, Nigeria, Bangladesh, and the Democratic Republic of the Congo. The emergence of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) threatens decades of progress, with treatment success rates for drug-resistant strains remaining well below those of drug-susceptible disease. Europe and Central Asia benefit from relatively strong health systems and high physician density, but face ageing populations, rising non-communicable disease burdens, and persistent East-West health outcome gradients. In Europe & Central Asia, tuberculosis mortality is near global averages, though the region exhibits a marked gradient between Western European countries with low rates and Central Asian nations facing higher burdens.
TB control rests on early case detection through symptom screening and molecular diagnostics (GeneXpert MTB/RIF), directly observed therapy short-course (DOTS) for drug-susceptible TB, and newer regimens like BPaL (bedaquiline-pretomanid-linezolid) for resistant strains. The BCG vaccine, developed over a century ago, provides partial protection against severe childhood TB but limited efficacy against pulmonary TB in adults. Preventive therapy with isoniazid or rifapentine for latent TB infection is critical for high-risk groups, particularly people living with HIV.
The mortality estimates presented on this page are derived from the Global Burden of Disease (GBD) study, produced by the Institute for Health Metrics and Evaluation (IHME). The GBD synthesizes data from vital registration systems, verbal autopsies, cancer registries, and surveillance networks across more than 200 countries and territories. Death rates are expressed per 100,000 population and are age-standardized, which adjusts for differences in age structure between populations so that comparisons across countries and over time reflect genuine differences in mortality risk rather than demographic composition.
The dataset typically covers the period from 1990 to 2023, although availability varies by country and cause. When interpreting the figures for tuberculosis in Europe & Central Asia, note that higher age-standardized rates indicate a greater mortality burden independent of whether a country's population is older or younger. Trends over time reveal whether public health interventions, economic development, and health system improvements have reduced or increased the toll of this condition in the region.
Disease-specific death rates measure the number of deaths directly attributed to tuberculosis per 100,000 people, after accounting for age structure. These rates capture both the prevalence of the condition and the likelihood of a fatal outcome once affected. In Europe & Central Asia, variation across countries may reflect differences in disease prevalence, access to treatment, diagnostic capacity, and the presence of comorbidities. Examining trends alongside health expenditure and intervention coverage helps identify where policy action has been most effective.